Skip to main content
Signal8
Launch Terminal

Alpha Tau Medical Ltd. (DRTS)

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The company is headquartered in Jerusalem, Israel.

Sector: Surgical & Medical Instruments & Apparatus

Industry: Biotechnology

Alpha Tau Medical Ltd. logo

Alpha Tau Medical Ltd.

NASDAQ:DRTSHealthcare
-1.28%$13.06
AH$13.06+0.00%vs close
Mkt Cap$1.21B
Float63.91M
O/S92.48M
Vol
$ Vol
RVOL
Inst Own8.6%
SI5.4%
Earnings
Dilution
Alpha Tau Medical Ltd. logoNASDAQ:DRTS$13.06-1.28%
Phase Distribution
29 lead-sponsored trials·18 active·6 completed
Not applicable29
(1 more as collaborator)
Status Overview
Not yet recruiting2
Recruiting14
Active, not recruiting4
Completed6
Stopped2
Unknown1

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
  • Not applicable
    Completed

    Alpha Radiation Emitters Device for the Treatment of Squamous Cell Carcinoma

    Diffusing Alpha Radiation Emitters Therapy (DaRT)

    Squamous Cell Carcinoma

    Enrollment
    28
    Start
    Feb 2017
    Primary Completion
    Jun 2019
    Completion
    Jun 2019
    NCT03015883
  • Not applicable
    Completed

    Alpha Radiation Emitters Device for the Treatment of Squamous Cell Carcinoma (DaRT)

    Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)

    Skin Squamous Cell Carcinoma

    Enrollment
    28
    Start
    Nov 2017
    Primary Completion
    Jul 2019
    Completion
    Jul 2019
    NCT03353077
  • Not applicable
    Active, not recruiting

    Alpha Radiation Emitters Device for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia (DaRT)

    Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)

    Skin Cancer, Mucosal Neoplasm of Oral Cavity +1

    Enrollment
    30
    Start
    Dec 2018
    Primary Completion
    Dec 2026est.
    Completion
    Dec 2026est.
    NCT03737734
  • Not applicable
    Terminated

    Alpha Radiation Emitters Device for the Treatment of Cutaneous, Mucosal and Superficial Soft Tissue Neoplasia (DaRT)

    Device: Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)

    Skin Cancer, Mucosal Neoplasm of Oral Cavity +1

    Enrollment
    2
    Start
    Jul 2021
    Primary Completion
    Oct 2024
    Completion
    Oct 2024
    NCT03886181
  • Not applicable
    Recruiting

    Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia.

    Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)

    Skin Cancer, Mucosal Neoplasm of Oral Cavity +1

    Enrollment
    30
    Start
    Oct 2020
    Primary Completion
    Jun 2026est.
    Completion
    Sep 2026est.
    NCT03889899
  • Not applicable
    Terminated

    Alpha Radiation Emitters Device for the Treatment of Newly Diagnosed Breast Carcinoma Patients With Distant Metastases

    Device: Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)

    Breast Carcinoma, Metastatic Breast Cancer +2

    Enrollment
    1
    Start
    Aug 2019
    Primary Completion
    Nov 2023
    Completion
    Nov 2023
    NCT03970967
  • Not applicable
    Active, not recruiting

    Alpha Radiation Emitters Device for the Treatment of Advanced Pancreatic Cancer

    Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)

    Pancreatic Cancer, Unresectable Pancreatic Cancer +2

    Enrollment
    37
    Start
    Oct 2020
    Primary Completion
    Oct 2026est.
    Completion
    Oct 2026est.
    NCT04002479
  • Not applicable
    Recruiting

    Alpha Radiation Emitters Device (DaRT) for the Treatment of of Malignant Cutaneous Tumors

    DaRT- Diffusing Alpha-emitters Radiation Therapy

    Skin Cancer, Cutaneous Tumor +1

    Enrollment
    80
    Start
    Apr 2022
    Primary Completion
    Jan 2027est.
    Completion
    Jan 2028est.
    NCT04068155
  • Not applicable
    Completed

    Feasibility Trial of Diffusing Alpha-emitter Radiation Therapy (DaRT) for Malignant Skin & Superficial Soft Tissue Tumors

    Diffusing Alpha-emitter Radiation Therapy

    Malignant Skin Tumor, Soft Tissue Tumor, Malignant

    Enrollment
    10
    Start
    Jan 2020
    Primary Completion
    Mar 2022
    Completion
    Mar 2022
    NCT04377360
  • Not applicable
    Recruiting

    Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia

    Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)

    Skin Cancer, Mucosal Neoplasm of Oral Cavity +1

    Enrollment
    56
    Start
    Dec 2020
    Primary Completion
    Jan 2027est.
    Completion
    Jul 2027est.
    NCT04534127
  • Not applicable
    Completed

    Retreatment With Intratumoral Diffusing Alpha Radiation Emitters

    Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)

    Skin Cancer, Mucosal Neoplasm of Oral Cavity +1

    Enrollment
    2
    Start
    Dec 2020
    Primary Completion
    Dec 2025
    Completion
    Dec 2025
    NCT04540588
  • Not applicable
    Completed

    Neoadjuvant Interstitial Brachytherapy Using Diffusing Alpha Emitters Radiation Therapy in Men With Prostate Cancer

    Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)

    Prostate Adenocarcinoma

    Enrollment
    1
    Start
    May 2022
    Primary Completion
    Oct 2025
    Completion
    Oct 2025
    NCT04543903
  • Not applicable
    Recruiting

    Alpha Radiation Emitters Device (DaRT) in Combination With Check Point Inhibitor for the Treatment of Recurrent Unresectable or mHNSCC

    Pembrolizumab

    Head and Neck Squamous Cell Carcinoma, Skin Cancer +1

    Enrollment
    48
    Start
    Nov 2021
    Primary Completion
    Dec 2026est.
    Completion
    Jun 2027est.
    NCT05047094
  • Not applicable
    Unknown status

    Neoadjuvant DaRT for Locally Advanced Oral Cavity SCC

    Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT

    Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma

    Enrollment
    79
    Start
    Mar 2025est.
    Primary Completion
    Dec 2025est.
    Completion
    Jun 2026est.
    NCT05065346
  • Observational
    Completed

    A Retrospective Analysis to Evaluate Long Term Outcomes of SCC Patients Previously Treated With Alpha DaRT

    -

    Squamous Cell Carcinoma, DaRT Treated Patients

    Enrollment
    33
    Start
    Jan 2022
    Primary Completion
    Mar 2022
    Completion
    Mar 2022
    NCT05125354
  • Not applicable
    Active, not recruiting

    Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Cutaneous Squamous Cell Carcinoma

    DaRT seeds

    Recurrent Squamous Cell Carcinoma

    Enrollment
    86
    Start
    Sep 2022
    Primary Completion
    Apr 2027est.
    Completion
    Apr 2027est.
    NCT05323253
  • Not applicable
    Recruiting

    Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Lung Cancer

    Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)

    Recurrent Lung Cancer, Lung Cancer

    Enrollment
    10
    Start
    Jul 2023
    Primary Completion
    Feb 2027est.
    Completion
    Feb 2027est.
    NCT05632913
  • Not applicable
    Recruiting

    Alpha Radiation Emitters Device for the Treatment of Advanced Pancreatic Cancer (Feasibility and Safety)

    Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)

    Pancreatic Cancer, Unresectable Pancreatic Cancer +2

    Enrollment
    15
    Start
    Aug 2023
    Primary Completion
    Nov 2026est.
    Completion
    Nov 2027est.
    NCT05657743
  • Not applicable
    Recruiting

    Alpha Radiation Emitters Device (DaRT) for Target Treatments of Malignant Tumors

    Experimental: DaRT seeds

    Malignant Tumor

    Enrollment
    100
    Start
    Mar 2023
    Primary Completion
    Apr 2027est.
    Completion
    Apr 2027est.
    NCT05781555
  • Not applicable
    Recruiting

    Alpha Radiation Emitters Device (DaRT) for the Treatment of Liver Metastases

    Diffusing Alpha Radiation Emitters Therapy (DaRT)

    Liver Metastases

    Enrollment
    10
    Start
    Oct 2023
    Primary Completion
    Feb 2027est.
    Completion
    Jul 2027est.
    NCT05829291
  • Not applicable
    Recruiting

    Alpha Radiation Emitters for the Treatment of Pancreatic Cancer for the Treatment of Locally Advanced Pancreatic Cancer

    DaRT seeds insertion

    Pancreatic Cancer, Unresectable Pancreatic Cancer +1

    Enrollment
    15
    Start
    May 2026
    Primary Completion
    Jan 2027est.
    Completion
    Jan 2028est.
    NCT06026943
  • Not applicable
    Recruiting

    A Study of Diffusing Alpha Radiation Therapy for Patients With Breast Carcinoma in Frail or Elderly Patients.

    Diffusing Alpha Radiation Emitters Therapy (DaRT)

    Breast Cancer, Recurrent Breast Cancer +1

    Enrollment
    10
    Start
    Feb 2024
    Primary Completion
    Jan 2026est.
    Completion
    Jun 2026est.
    NCT06202118
  • Not applicable
    Recruiting

    Alpha Radiation Emitters Device (DaRT) for the Treatment of Non-Metastatic Locally Recurrent Prostate Cancer.

    Experimental: DaRT seeds

    Non-metastatic Prostate Cancer, Locally Recurrent Prostate Cancer

    Enrollment
    10
    Start
    Mar 2024
    Primary Completion
    Jun 2027est.
    Completion
    Jun 2027est.
    NCT06202248
  • Not applicable
    Not yet recruiting

    Alpha Radiation Emitters Device for the Treatment of Primary and Recurrent Squamous Cell Carcinoma of the Vulva (DaRT).

    DaRT seeds

    Carcinoma of the Vulva, Recurrent Carcinoma of the Vulva

    Enrollment
    10
    Start
    Apr 2024est.
    Primary Completion
    Apr 2026est.
    Completion
    Dec 2026est.
    NCT06202339
  • Not applicable
    Recruiting

    Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous SCC for Immunocompromised Patients

    DaRT seeds

    Squamous Cell Carcinoma, Alpha Radiation +4

    Enrollment
    28
    Start
    Jan 2026
    Primary Completion
    Dec 2026est.
    Completion
    Dec 2026est.
    NCT06615635

1-25 of 29

Search ClinicalTrials.gov for “Alpha Tau Medical”